Synthesis and Comparative <i>In Vivo</i> Evaluation of Site-Specifically Labeled Radioimmunoconjugates for DLL3-Targeted ImmunoPET
Sai Kiran Sharma, Pierre Adumeau, Outi Keinänen, Vikram Sisodiya, Hetal Sarvaiya, Robert Tchelepi, Joshua A. Korsen, Jacob Pourat, Kimberly J. Edwards, Ashwin Ragupathi, Omar Hamdy, Laura R. Saunders, Charles M. Rudin, John T. Poirier, Jason S. Lewis, Brian M. Zeglis
Abstract
performance of the PODS-based radioimmunoconjugate and suggest that a stable, well-defined DAR2 radiopharmaceutical may be suitable for the clinical immunoPET of DLL3-expressing cancers.
Topics & Concepts
ChemistryIn vivoTCEPPretargetingImmunoconjugateCancer researchPharmacologyMonoclonal antibodyAntibodyBiochemistryRadioimmunotherapyImmunologyPhosphineCatalysisMedicineBiologyBiotechnologyRadiopharmaceutical Chemistry and ApplicationsPeptidase Inhibition and AnalysisMonoclonal and Polyclonal Antibodies Research